The IL-6/gp130/STAT3 signaling axis: recent advances towards specific inhibition
Highlights • IL-6 has pro-inflammatory and anti-inflammatory activities. • IL-6 is involved in many autoimmune diseases. • IL-6 trans-signaling via the soluble IL-6 receptor is mainly pro-inflammatory. • Classic IL-6 signaling via the membrane bound IL-6R is regenerative and protective. • Specific b...
Gespeichert in:
| Veröffentlicht in: | Current opinion in immunology 2015-06, Vol.34, p.75-82 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 82 |
|---|---|
| container_issue | |
| container_start_page | 75 |
| container_title | Current opinion in immunology |
| container_volume | 34 |
| creator | Garbers, Christoph Aparicio-Siegmund, Samadhi Rose-John, Stefan |
| description | Highlights • IL-6 has pro-inflammatory and anti-inflammatory activities. • IL-6 is involved in many autoimmune diseases. • IL-6 trans-signaling via the soluble IL-6 receptor is mainly pro-inflammatory. • Classic IL-6 signaling via the membrane bound IL-6R is regenerative and protective. • Specific blockade of IL-6 trans-signaling might be a superior alternative to global blockade of IL-6. |
| doi_str_mv | 10.1016/j.coi.2015.02.008 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1732809013</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0952791515000370</els_id><sourcerecordid>1698390423</sourcerecordid><originalsourceid>FETCH-LOGICAL-c441t-77182cdda94646e00b4af10e49d5f1a225f47dffdb58f7022162673ed35c40b33</originalsourceid><addsrcrecordid>eNqNkU1v1DAURS1ERYfCD2CDsmSTzHv-iBOQkKoKaKWRWqnD2nLsl6mHTDLEmdL-exxNYcGiYvU2917pncPYO4QCAcvltnBDKDigKoAXANULtsBK1zkIzV-yBdSK57pGdcpex7gFAKUEvGKnXGlZK8QFu1nfUXa1ysvlZo8Clrfr87XIYtj0tgv9JrMPIX7MRnLUT5n197Z3FLNp-GVHH7O4Jxfa4LLQ34UmTGHo37CT1naR3j7dM_b965f1xWW-uv52dXG-yp2UOOVaY8Wd97aWpSwJoJG2RSBZe9Wi5Vy1Uvu29Y2qWg2cY8lLLcgL5SQ0QpyxD8fd_Tj8PFCczC5ER11nexoO0aAWvIIa8D-iZV2JGiSfo3iMunGIcaTW7Mews-OjQTAzc7M1ibmZmRvgJjFPnfdP84dmR_5v4w_kFPh0DFDicR9oNNEFSiB9SGAn49Pgc_Of_2m7ZCY42_2gR4rb4TAmV-kLE1PB3M7SZ-eokm-hQfwGN--jww</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1698390423</pqid></control><display><type>article</type><title>The IL-6/gp130/STAT3 signaling axis: recent advances towards specific inhibition</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Garbers, Christoph ; Aparicio-Siegmund, Samadhi ; Rose-John, Stefan</creator><creatorcontrib>Garbers, Christoph ; Aparicio-Siegmund, Samadhi ; Rose-John, Stefan</creatorcontrib><description>Highlights • IL-6 has pro-inflammatory and anti-inflammatory activities. • IL-6 is involved in many autoimmune diseases. • IL-6 trans-signaling via the soluble IL-6 receptor is mainly pro-inflammatory. • Classic IL-6 signaling via the membrane bound IL-6R is regenerative and protective. • Specific blockade of IL-6 trans-signaling might be a superior alternative to global blockade of IL-6.</description><identifier>ISSN: 0952-7915</identifier><identifier>EISSN: 1879-0372</identifier><identifier>DOI: 10.1016/j.coi.2015.02.008</identifier><identifier>PMID: 25749511</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Allergy and Immunology ; Animals ; Antibodies, Monoclonal, Humanized - therapeutic use ; Humans ; Inflammation - drug therapy ; Inflammation - immunology ; Interleukin-6 - immunology ; Interleukin-6 - metabolism ; Receptors, Interleukin-6 - metabolism ; Signal Transduction ; STAT3 Transcription Factor - metabolism</subject><ispartof>Current opinion in immunology, 2015-06, Vol.34, p.75-82</ispartof><rights>Elsevier Ltd</rights><rights>2015 Elsevier Ltd</rights><rights>Copyright © 2015 Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c441t-77182cdda94646e00b4af10e49d5f1a225f47dffdb58f7022162673ed35c40b33</citedby><cites>FETCH-LOGICAL-c441t-77182cdda94646e00b4af10e49d5f1a225f47dffdb58f7022162673ed35c40b33</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.coi.2015.02.008$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25749511$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Garbers, Christoph</creatorcontrib><creatorcontrib>Aparicio-Siegmund, Samadhi</creatorcontrib><creatorcontrib>Rose-John, Stefan</creatorcontrib><title>The IL-6/gp130/STAT3 signaling axis: recent advances towards specific inhibition</title><title>Current opinion in immunology</title><addtitle>Curr Opin Immunol</addtitle><description>Highlights • IL-6 has pro-inflammatory and anti-inflammatory activities. • IL-6 is involved in many autoimmune diseases. • IL-6 trans-signaling via the soluble IL-6 receptor is mainly pro-inflammatory. • Classic IL-6 signaling via the membrane bound IL-6R is regenerative and protective. • Specific blockade of IL-6 trans-signaling might be a superior alternative to global blockade of IL-6.</description><subject>Allergy and Immunology</subject><subject>Animals</subject><subject>Antibodies, Monoclonal, Humanized - therapeutic use</subject><subject>Humans</subject><subject>Inflammation - drug therapy</subject><subject>Inflammation - immunology</subject><subject>Interleukin-6 - immunology</subject><subject>Interleukin-6 - metabolism</subject><subject>Receptors, Interleukin-6 - metabolism</subject><subject>Signal Transduction</subject><subject>STAT3 Transcription Factor - metabolism</subject><issn>0952-7915</issn><issn>1879-0372</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkU1v1DAURS1ERYfCD2CDsmSTzHv-iBOQkKoKaKWRWqnD2nLsl6mHTDLEmdL-exxNYcGiYvU2917pncPYO4QCAcvltnBDKDigKoAXANULtsBK1zkIzV-yBdSK57pGdcpex7gFAKUEvGKnXGlZK8QFu1nfUXa1ysvlZo8Clrfr87XIYtj0tgv9JrMPIX7MRnLUT5n197Z3FLNp-GVHH7O4Jxfa4LLQ34UmTGHo37CT1naR3j7dM_b965f1xWW-uv52dXG-yp2UOOVaY8Wd97aWpSwJoJG2RSBZe9Wi5Vy1Uvu29Y2qWg2cY8lLLcgL5SQ0QpyxD8fd_Tj8PFCczC5ER11nexoO0aAWvIIa8D-iZV2JGiSfo3iMunGIcaTW7Mews-OjQTAzc7M1ibmZmRvgJjFPnfdP84dmR_5v4w_kFPh0DFDicR9oNNEFSiB9SGAn49Pgc_Of_2m7ZCY42_2gR4rb4TAmV-kLE1PB3M7SZ-eokm-hQfwGN--jww</recordid><startdate>20150601</startdate><enddate>20150601</enddate><creator>Garbers, Christoph</creator><creator>Aparicio-Siegmund, Samadhi</creator><creator>Rose-John, Stefan</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7T5</scope><scope>H94</scope></search><sort><creationdate>20150601</creationdate><title>The IL-6/gp130/STAT3 signaling axis: recent advances towards specific inhibition</title><author>Garbers, Christoph ; Aparicio-Siegmund, Samadhi ; Rose-John, Stefan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c441t-77182cdda94646e00b4af10e49d5f1a225f47dffdb58f7022162673ed35c40b33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Allergy and Immunology</topic><topic>Animals</topic><topic>Antibodies, Monoclonal, Humanized - therapeutic use</topic><topic>Humans</topic><topic>Inflammation - drug therapy</topic><topic>Inflammation - immunology</topic><topic>Interleukin-6 - immunology</topic><topic>Interleukin-6 - metabolism</topic><topic>Receptors, Interleukin-6 - metabolism</topic><topic>Signal Transduction</topic><topic>STAT3 Transcription Factor - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Garbers, Christoph</creatorcontrib><creatorcontrib>Aparicio-Siegmund, Samadhi</creatorcontrib><creatorcontrib>Rose-John, Stefan</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Current opinion in immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Garbers, Christoph</au><au>Aparicio-Siegmund, Samadhi</au><au>Rose-John, Stefan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The IL-6/gp130/STAT3 signaling axis: recent advances towards specific inhibition</atitle><jtitle>Current opinion in immunology</jtitle><addtitle>Curr Opin Immunol</addtitle><date>2015-06-01</date><risdate>2015</risdate><volume>34</volume><spage>75</spage><epage>82</epage><pages>75-82</pages><issn>0952-7915</issn><eissn>1879-0372</eissn><abstract>Highlights • IL-6 has pro-inflammatory and anti-inflammatory activities. • IL-6 is involved in many autoimmune diseases. • IL-6 trans-signaling via the soluble IL-6 receptor is mainly pro-inflammatory. • Classic IL-6 signaling via the membrane bound IL-6R is regenerative and protective. • Specific blockade of IL-6 trans-signaling might be a superior alternative to global blockade of IL-6.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>25749511</pmid><doi>10.1016/j.coi.2015.02.008</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0952-7915 |
| ispartof | Current opinion in immunology, 2015-06, Vol.34, p.75-82 |
| issn | 0952-7915 1879-0372 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1732809013 |
| source | MEDLINE; ScienceDirect Journals (5 years ago - present) |
| subjects | Allergy and Immunology Animals Antibodies, Monoclonal, Humanized - therapeutic use Humans Inflammation - drug therapy Inflammation - immunology Interleukin-6 - immunology Interleukin-6 - metabolism Receptors, Interleukin-6 - metabolism Signal Transduction STAT3 Transcription Factor - metabolism |
| title | The IL-6/gp130/STAT3 signaling axis: recent advances towards specific inhibition |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T16%3A04%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20IL-6/gp130/STAT3%20signaling%20axis:%20recent%20advances%20towards%20specific%20inhibition&rft.jtitle=Current%20opinion%20in%20immunology&rft.au=Garbers,%20Christoph&rft.date=2015-06-01&rft.volume=34&rft.spage=75&rft.epage=82&rft.pages=75-82&rft.issn=0952-7915&rft.eissn=1879-0372&rft_id=info:doi/10.1016/j.coi.2015.02.008&rft_dat=%3Cproquest_cross%3E1698390423%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1698390423&rft_id=info:pmid/25749511&rft_els_id=S0952791515000370&rfr_iscdi=true |